Back to results
US 12,529,037 B2Granted
M1 virus mutant and use thereof
AssigneeGuangzhou Virotech Pharmaceutical Co., Ltd.
InventorsGuangmei Yan, Yuan Lin, Li Guo, Ziqing Lin, Guang'en Wu
Life of this patent
Estimating the term…
Abstract
Provided is an M1 virus. Further provided are a series of uses of said virus. The uses include, but are not limited to, viral vectors, anti-tumor agents, and pharmaceutical compositions. Said virus can effectively inhibit the growth of various tumor cells, and at the same time, has tumor targeting properties and is non-toxic to normal cells. Said virus can be administrated by means of intravenous injection, having operational convenience.
Claims19
An M1 virus comprising:
- an NS3 protein comprising an amino acid sequence having at least 90% or at least 91% or at least 92% or at least 93% or at least 94% or at least 95% or at least 96% or at least 97% or at least 98% or at least 99% or at least 99.5% or at least 99.8% or at least 99.9% or 100% sequence identity with an amino acid sequence shown as SEQ ID NO:
- 8;
- and in which amino acid residue M at 358th site in SEQ ID NO:8 is substituted into G, A, L, I, V, P, S, Q, T, C, N, F, Y, D, K, R or H;
- and/or
- an envelope protein comprising an amino acid sequence having at least 90% or at least 91% or at least 92% or at least 93% or at least 94% or at least 95% or at least 96% or at least 97% or at least 98% or at least 99% or at least 99.5% or at least 99.8% or at least 99.9% or 100% sequence identity with an amino acid sequence shown as SEQ ID NO:
- 12 or SEQ ID NO:
- 31;
- and in which amino acid residue K at 4th site in the SEQ ID NO:
- 12 or amino acid residue E at 4th site in the SEQ ID NO:
- 31 is substituted into M, L, I, V, S, C, N, or D.
7 more elements
An M1 virus comprising:
- an NS3 protein and an envelope protein E2 encoded by a nucleotide sequence of the M1 virus, wherein
- the NS3 protein comprising an amino acid sequence having at least 90% or at least 91% or at least 92% or at least 93% or at least 94% or at least 95% or at least 96% or at least 97% or at least 98% or at least 99% or at least 99.5% or at least 99.8% sequence identity with the amino acid sequence shown as SEQ ID NO:
- 8, and in which amino acid residue M at 358th site in the SEQ ID NO:8 is substituted into G, A, L, I, V, P, S, Q, T, C, N, F, Y, D, K, R or H;
- and/or
- the envelope protein E2 comprising an amino acid sequence having at least 90% or at least 91% or at least 92% or at least 93% or at least 94% or at least 95% or at least 96% or at least 97% or at least 98% or at least 99% or at least 99.5% or at least 99.8% sequence identity with the amino acid sequence shown as SEQ ID NO:
- 12 or SEQ ID NO:
- 31, and in which amino acid residue K at 4th site in the SEQ ID NO:
- 12 or amino acid residue E at 4th site in the SEQ ID NO:
- 31 is substituted into M, L, I, V, S, C, N, or D.
6 more elements
An M1 virus, comprising:
- an NS3 protein comprising an amino acid sequence in which amino acid residue M at 358th site in SEQ ID NO:8 is substituted into G, A, L, I, V, P, S, Q, T, C, N, F, Y, D, K, R or H;
- and/or
- an envelope protein E2 comprising an amino acid sequence in which amino acid residue K at the 4th site in SEQ ID NO:
- 12 or amino acid residue E at the 4th site in SEQ ID NO:
- 31 is substituted into M, L, I, V, S, C, N, or D.
2 more elements
Dependencies are inferred from the claim text.